Abbott Laboratories

NYSE:ABTUnited States

Nov 1, 2024

Show headlines and story abstract

• DJ Abbott's Baby-Formula Lawsuit Win Could Decrease Liabilities -- Market Talk, from 1:33PM ET on Friday Nov 01, 2024 by Dow Jones

  1:33PM ET on Friday Nov 01, 2024 by Dow Jones
  Companies Mentioned: ABT
  
  1333 ET - JPMorgan analysts feel more bullish on Abbott Laboratories after a Missouri court cleared the company of liability in a case concerning its baby formula. The verdict is in contrast to a previous ruling earlier this year that resulted in $495 million against Abbott in compensation and damages in a similar case. "In our discussions many investors had been assuming $2 billion to $3 billion as the total liability for Abbott," analysts say in a research note. But after the win, "that could decrease by $500 million to $1 billion," they say. Abbott stands to benefit from backing by the medical community, after the FDA, CDC and NIH published a joint statement which said there is no conclusive evidence preterm infant formula causes necrotizing enterocolitis, analysts add. Abbott rises 5%. (connor.hart@wsj.com)
  

• DJ Abbott Laboratories Up Over 5%, On Track for Largest Percent Increase Since April 2023 -- Data Talk, from 11:03AM ET on Friday Nov 01, 2024 by Dow Jones

  11:03AM ET on Friday Nov 01, 2024 by Dow Jones
  Companies Mentioned: ABT
  
  Abbott Laboratories (ABT) is currently at $119.28, up $5.91 or 5.21%
  
  --Would be highest close since Oct. 18, 2024, when it closed at $119.39
  
  --On pace for largest percent increase since April 19, 2023, when it rose 7.82%